AIM ImmunoTech raises $2.4M to fund Phase 3 Ampligen trial activities

What's the deal? AIM ImmunoTechDealroom has a profile for this one. Try Dealroom → has announced a registered direct offering of 7.51 million shares at $0.325 per share, expected to generate roughly $2.4M in gross proceeds. The funds will support clinical drug supply manufacturing and planned Phase 3 trial activities for its lead investigational product, Ampligen.

The offering also includes unregistered Series I warrants for additional shares, pending stockholder approval.

Why now? The capital raise comes as AIM ImmunoTech prepares to advance Ampligen through Phase 3 clinical trials — a costly and critical stage of drug development. The company needs fresh funds to manufacture clinical drug supplies and keep its trial timeline on track.

What could go wrong? At $0.325 per share, the offering price signals significant dilution for existing shareholders. Phase 3 trials are expensive and uncertain — $2.4M is a modest sum for this stage, which could mean the company will need to raise more capital down the line. Stockholder approval for the warrant component also remains pending.

The signal: AIM ImmunoTech is classified as a mature-stage company on Dealroom, yet its need to raise just $2.4M through a heavily discounted direct offering underscores how capital-constrained even established biotech firms can be when funding late-stage trials. The near-20% pre-market stock surge suggests the market is pricing in optionality — betting that Phase 3 progress for Ampligen could unlock far more value than the dilution costs today.

Read more: Intellectia